Anthropometric assessment of men with colorectal cancer after dietary supplement with Agaricus sylvaticus fungus

Fortes, Renata Costa; Silva, João Rodrigo de Lavor e; Novaes, María Rita Carvalho Garbi

doi:10.1590/s2237-93632012000400003

Cited by 4 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results agree with those of other studies that indicate prevalence of colorretal cancer in patients over 50 years of age [11][12][13] . According to Cozerattolini and Gallon 14 , more than 90% cases of colorectal cancers occur in subjects over 50 years of age, and 75% affect individuals without risk factors other than age.…”

Section: Discussionsupporting

confidence: 93%

Quality of life from oncological patients with definitive and temporary colostomy

Fortes¹,

Monteiro

Kimura³

2012

J. Coloproctol. (Rio J.)

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Quality of life from oncological patients with definitive and temporary colostomy

Fortes¹,

Monteiro

Kimura³

2012

J. Coloproctol. (Rio J.)

Self Cite

View full text Add to dashboard Cite

“…A large variety of cancer entities, studied sample sizes, outcomes, treatment durations and observation times were seen ( Table 1). The medicinal mushrooms investigated were Agaricus sylvaticus (two trials) (Fortes et al, 2008;Costa Fortes et al, 2010;Costa Fortes and Carvalho Garbi Novaes, 2011;Valadares et al, 2013), Agaricus blazei murill (two trials) (Ahn et al, 2004;Tangen et al, 2015), Antrodia cinnamomea (one trial) (Tsai et al, 2016), Coriolus versicolor (one trial) (Chay et al, 2017) and Ganoderma lucidum (three trials) (Gao et al, 2003a;Oka et al, 2010;Zhao et al, 2012). All mushrooms were administered orally.…”

Section: Resultsmentioning

confidence: 99%

“…All mushrooms were administered orally. Four articles were by Fortes et al and they described different results of a study with Agaricus sylvaticus which included 56 colorectal cancer patients (Fortes et al, 2008;Fortes et al, 2009;Costa Fortes et al, 2010;Costa Fortes and Carvalho Garbi Novaes, 2011). These four articles were presented as one study.…”

Section: Resultsmentioning

confidence: 99%

“…Fortes et al investigated 56 patients with colorectal cancer after surgery over a period of 6 months, randomly assigned to the intake Agaricus sylvaticus or placebo (Costa Fortes et al, 2010). Analyses did not show significant differences regarding quality of life, however the results after 6 months showed a tendency toward better mood and sleep, and less gastrointestinal symptoms and pain in the verum group.…”

Section: Quality Of Lifementioning

confidence: 99%

“…Fortes et al observed in a RCT beneficial hematological and glycaemic effects of dietary supplementation with Agaricus sylvaticus in patients with colorectal cancer after surgery (Fortes et al, 2008;Costa Fortes et al, 2010;Costa Fortes and Carvalho Garbi Novaes, 2011). The verum group showed significant within-group reductions of fasting plasma glucose, cholesterol, creatinine, aspartate aminotransferase, alanine aminotransferase, immunoglobulin A, immunoglobulin M, systolic and diastolic blood pressure and an improvement in hematological parameters (e.g., hemoglobin, hematocrit, erythrocytes, iron) after 3 and 6 months of treatment, whereas in the placebo group no significant within-group changes were observed.…”

Section: Hematological Parametersmentioning

confidence: 99%

See 2 more Smart Citations

Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review

et al. 2020

View full text Add to dashboard Cite

Medicinal mushrooms are widely used in East Asia for the treatment of various diseases, especially in complementary cancer care. While there is a growing interest in medicinal mushrooms in Western countries and an increasing number of pre-clinical studies indicate distinct anti-cancer and regenerative properties, little is known about their potential relevance for clinical practice. This review aims to provide an overview of the clinical evidence, significance and potential role of medicinal mushrooms in complementary cancer care. Scientific databases for (randomized) controlled clinical trials evaluating whole spectrum formulations of medicinal mushrooms (mushroom powder and mushroom extracts) in cancer patients during and/or after conventional oncological treatment were searched. Eight studies met our inclusion criteria (eight randomized controlled trials, one controlled clinical trial). The medicinal mushrooms investigated were Agaricus sylvaticus (two trials), Agaricus blazei murill (two trials), Antrodia cinnamomea (one trial), Coriolus versicolor (one trial) and Ganoderma lucidum (three trials); all were compared to placebo and administered orally. A variety of cancer entities, outcomes and treatment durations were observed. Study results suggested beneficial effects of medicinal mushrooms, particularly quality of life and reduction of adverse effects of conventional therapies. Also, positive effects on antitumor activity and immunomodulation were reported, e.g., an increased activity of natural killer cells. In addition, results might suggest a longer survival of cancer patients receiving mushroom preparations, although in most studies this was not significant when compared to placebo. Adverse events of treatment with medicinal mushrooms were poorly reported; gastrointestinal reactions and a decrease in platelet cell count occurred in some cases. The methodological quality of most studies was generally unsatisfying and most results were insufficiently reported in several respects. Medicinal mushrooms may have a therapeutic potential for cancer patients during and after conventional oncological care with regards to quality of life, reduction of adverse effects of conventional care and possibly other surrogate parameters like immune function. There is an urgent need to investigate the safety and possible interactions of medicinal mushrooms. High-quality clinical research is warranted in order to clarify the potential of medicinal mushrooms in cancer therapy.

show abstract

N-acetyl cysteine and mushroom Agaricus sylvaticus supplementation decreased parasitaemia and pulmonary oxidative stress in a mice model of malaria

Gomes

Silva

Gomes

et al. 2015

Malar J

View full text Add to dashboard Cite

BackgroundMalaria infection can cause high oxidative stress, which could lead to the development of severe forms of malaria, such as pulmonary malaria. In recent years, the role of reactive oxygen species in the pathogenesis of the disease has been discussed, as well as the potential benefit of antioxidants supplementation. The aim of this study was to investigate the effects of N-acetyl cysteine (NAC) or mushroom Agaricus sylvaticus supplementation on the pulmonary oxidative changes in an experimental model of malaria caused by Plasmodium berghei strain ANKA.MethodsSwiss male mice were infected with P. berghei and treated with NAC or AS. Samples of lung tissue and whole blood were collected after one, three, five, seven or ten days of infection for the assessment of thiobarbituric acid reactive substances (TBARS), trolox equivalent antioxidant capacity (TEAC), nitrites and nitrates (NN) and to assess the degree of parasitaemia.ResultsAlthough parasitaemia increased progressively with the evolution of the disease in all infected groups, there was a significant decrease from the seventh to the tenth day of infection in both antioxidant-supplemented groups. Results showed significant higher levels of TEAC in both supplemented groups, the highest occurring in the group supplemented with A. sylvaticus. In parallel, TBARS showed similar levels among all groups, while levels of NN were higher in animals supplemented with NAC in relation to the positive control groups and A. sylvaticus, whose levels were similar to the negative control group.ConclusionOxidative stress arising from plasmodial infection was attenuated by supplementation of both antioxidants, but A. sylvaticus proved to be more effective and has the potential to become an important tool in the adjuvant therapy of malaria.Electronic supplementary materialThe online version of this article (doi:10.1186/s12936-015-0717-0) contains supplementary material, which is available to authorized users.

show abstract

Anthropometric assessment of men with colorectal cancer after dietary supplement with Agaricus sylvaticus fungus

Cited by 4 publications

References 13 publications

Quality of life from oncological patients with definitive and temporary colostomy

Quality of life from oncological patients with definitive and temporary colostomy

Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review

N-acetyl cysteine and mushroom Agaricus sylvaticus supplementation decreased parasitaemia and pulmonary oxidative stress in a mice model of malaria

Contact Info

Product

Resources

About